Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars & Generics

Set Alert for Biosimilars & Generics

US Biosimilar Approvals In 2021 Were Few But Included Many Firsts

While US biosimilar approvals have been somewhat thin on the ground in 2021 – with the pandemic driving inspection-related delays for multiple products – there were nevertheless several firsts this year, including the first two interchangeables and the first ophthalmic biosimilar.

Biosimilars Approvals

Is CREATES Act Equipped To Handle Biosimilar Complaints?

Biosimilar sponsors need multiple reference product lots and expiration dates, and questions remain about whether they can obtain enough to fulfill all regulatory requirements under a CREATES Act mandate, Teva attorney says.

Biosimilars Intellectual Property

EFPIA Unimpressed By Proposals For Tackling EU Medicines Shortages

Further analysis is under way, but first impressions by EU R&D industry group EFPIA of policy proposals for tackling drug shortages are not good.

Europe Supply Chain

ANDA Sponsors Given More Paperwork, But New Cover Letter Could Actually Be A Time-Saver

Optional checklists will help ensure submissions have all the required information.

Generic Drugs Review Pathway

US FDA Hoping To Spur More ANDA Pre-Submission Meetings During GDUFA III

The FDA believes conducting a pre-submission meeting when a complex generic application has unusual elements can increase the likelihood of a first-cycle approval.

Generic Drugs User Fees

FDA Slams Citizen Petition: Harsh Language, FTC Referral Suggest Tougher Stance On ANDA Delay Tactics

While the FTC referral is not unique, this seems the first time US FDA has cited intent to delay generic approval as a ground for denying a citizen petition. With Califf's confirmation hearing suggesting some bipartisan consensus on the issue, FDA might soon find itself with new powers.

Generic Drugs Legal Issues

Will FTC Injunction Against Shkreli’s Company Deter Brands From Pursuing Anti-Generic Actions?

Other companies have largely halted practices at issue in the ‘diabolical anticompetitive plan’ undertaken by Shkreli’s former firm. FTC did not challenge the price hike for Daraprim itself, but did cite an effort to block release of sales data and other tactics to discourage generics.

Legal Issues Enforcement

Holding ANDA Labeling Review Until Late Cycle Could Minimize Delays From Last-Minute Changes

A GDUFA III adjustment could allow more labeling changes during the review cycle and reduce assessment cycles.

Generic Drugs User Fees

Off-Patent Industry Calls For Security Of Supply Legislation In EU

Medicines for Europe has urged the European Commission to enshrine security of supply considerations for essential medicines into legislation. Without these, it says, additional cost containment measures for off-patent medicines under consideration by member states could threaten access by making production unsustainable for manufacturers.

Supply Chain Generic Drugs

How Star Wars Explains Biosimilar Labeling Problems

US FDA largely writes biosimilar labels that are the same as their reference products even though it’s not required, which could hinder product development and uptake, experts say.

Biosimilars Research & Development

EU Legislators Firm Up Commission’s Plans To Overhaul Pharma Rules

Efforts to overhaul the EU pharmaceutical legislation have been given added impetus after the European Parliament called for action to boost innovation and medicines access, shore up manufacturing and supply chains, and examine the link between R&D spending and drug prices.

Europe Legislation

Health Canada Ponders UK Model On Easing Biosimilar Study Requirements

Discussions are ongoing at Health Canada on the feasibility of adopting the UK model of easing clinical study requirements for biosimilars, said director general Celia Lourenco at a recent event. Meanwhile, the US FDA’s stance is unchanged for now.

Regulation Biosimilars
See All
UsernamePublicRestriction

Register